Lyon, France (ots/PRNewswire) - - First New Vaccine Against Polio in Decades to Be Used in Egypt, Part of Innovative WHO Strategy Sanofi pasteur, the vaccines business of the sanofi-aventis group, has received a license from the Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) for a new polio vaccine, which is the first new vaccine ...
LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a Pharmaceutical company based in AUSTRIA, announce the signing of an agreement granting CSC the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in Austria and other countries in Central and Eastern Europe. ALOXI® is ...
Espoo, Finland (ots/PRNewswire) - At its meeting held yesterday evening, the Board of Directors of Orion Corporation, which was elected yesterday at the Annual General Meeting of Shareholders, has re-elected Erkki Etola as Vice Chairman. Orion Corporation Jukka Viinanen Olli Huotari President and CEO General Counsel ...
Princeton, New Jersey (ots/PRNewswire) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment. Under the terms of the ...
Espoo, Finland (ots/PRNewswire) - At the Annual General Meeting of Orion Corporation held today, the following decisions were made: - A dividend of EUR 0.55 per share will be paid for 2004, payment date 5 April 2005. - Seven Board members were elected in accordance with the proposal by Board of Directors. Erkki Etola, Eero Karvonen, Matti Kavetvuo, Leena Palotie, Vesa Puttonen and Heikki Vapaatalo were ...
Espoo, Finland (ots/PRNewswire) - In his presentation of the 2004 Financial Statements to the Annual General Meeting of Orion Corporation, starting at 5 pm today in Helsinki, Mr. Jukka Viinanen, CEO of the Orion Group, will inform that the profitability of the Orion Group has shown very positive development in the first months of 2005 compared to the corresponding ...
Lyon, France (ots/PRNewswire) - - Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee ...
Istanbul, Turkey (ots/PRNewswire) - The inventor of extracorporeal shockwave lithotripsy (ESWL), Dornier MedTech, introduces the Compact Delta II lithotripter during the 20th annual European Association of Urology meeting. The Compact Delta II is based upon superior technology from the most widely sold lithotripter to date, the Compact Delta. This ...
Paris (ots/PRNewswire) - - New Indication Means More Patients Could Benefit From Earlier Treatment Bristol-Myers Squibb announces the approval of Taxol(r) (paclitaxel) for the treatment of early stage node-positive breast cancer following standard anthracycline and cyclophosphamide (AC) therapy. According to the approval, adjuvant treatment with Taxol should ...
Lyon, France (ots/PRNewswire) - - Submits Supplemental License Application Sanofi pasteur, the vaccines business of the sanofi-aventis Group, is seeking US government approval to broaden the age indication for its new meningococcal vaccine Menactra(TM) (Meningococcal [Groups A, C, Y and W-135] ...
Duluth, Georgia (ots/PRNewswire) - - Vaccine provides new hope for avian flu epidemic Merial today announced the introduction of a new inactivated vaccine, GALLIMUNE(R) Flu H5N9, developed and shown to be effective specifically for use against the highly pathogenic avian influenza virus H5N1 that has caused devastating economic losses in the poultry industry in Asia, and which has been linked to the deaths of ...
Lilongwe, Malawi (ots/PRNewswire) - The Abbott Fund, Baylor College of Medicine and the Government of Malawi have announced they will partner in the establishment of Malawi's first center dedicated to providing care and treatment for children with HIV/AIDS. Construction of the new clinic on the Kamuzu Central ...
Antwerp, Belgium (ots/PRNewswire) - - Results from RIO-Europe trial demonstrated that first-year improvements in cardiovascular risk factors are seen through two-year study period Luc Van Gaal, M.D. Principal Investigator RIO-Europe On behalf of the RIO Steering Committee The results of a two-year phase III study in 1,507 ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Fourth quarter 2004 net revenue of US$493.2 million, up 20% from same quarter in 2003 - Record backlog of US$2.6 billion as of Dec. 31, 2004 Quintiles Transnational Corp. today announced financial results for the year and quarter ended Dec. 31, 2004. Net revenue for 2004 was US$1.78 billion versus US$1.63 billion in 2003. Contribution ...
Basel, Switzerland (ots/PRNewswire) - - New Study Published Today Provides Further Evidence of the Benefit of Avastin(R) for Patients With Advanced Colorectal Cancer Data published for the first time today in the leading Journal of Clinical Oncology showed that the unique new cancer drug Avastin keeps ...
INGELHEIM, Germany,, February 28 (ots/PRNewswire) - - Tipranavir/r More Effective Than Lopinavir/r in Large-Scale Studies of Treatment-Experienced HIV-Positive Patients New data from multiple analyses presented last week at the 12th Conference on Retroviruses and Opportunistic Infections support the efficacy of the investigational non-peptidic protease ...
LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...
Madrid, Spain (ots/PRNewswire) - PharmaMar: - Yondelis: - Due to the good results presented at the ASCO (American Society of Clinical Oncology) meeting, the randomised pivotal trial on soft-tissue sarcoma was expanded so as to compile a dossier for a regulatory application. - Results presented on ovarian cancer formed the basis for preparing Phase III trials in combination with Doxil. - The FDA (Food and Drug Administration) granted orphan ...
Santa Clara, California (ots/PRNewswire) - Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, today announced that the San Francisco County Superior Court has granted a Temporary Restraining Order ("TRO") against defendants ...
Madrid, Spain (ots/PRNewswire) - PharmaMar announces that its second most advanced marine-derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in both prostate and bladder cancers. Phase II trial in Prostate Cancer This is the first trial of Aplidin in solid tumours to be carried out in the United States (US). This study will focus ...
Copenhagen, Denmark (ots/PRNewswire) - Gastrotech Pharma A/S announced today that Dr. Hans T. Schambye has been appointed as its Chief Executive Officer. He replaces Professor Claes Post who will continue to serve the company as a member of Gastrotech's Board of Directors and Senior Vice President. Dr. Post will focus entirely on identification and evaluation of ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the original target of 400 subjects for its Canadian Phase III psoriasis trial for its lead immunosuppressive compound, ISA247 has been reached. Due to the enthusiasm of our investigators and the willingness of patients to participate in the trial, the Company will allow approximately 80 ...
Laval, Canada (ots/PRNewswire) - - Danish Contract Research Organization Will Help Double LAB Research's Revenues LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company with a focus on inhalation delivery, today announced it has acquired all shares of Scantox, Biologisk Laboratorium A/S (Denmark), the leading Scandinavian, non- clinical contract research organization, for a total cash consideration of 28 million ...
San Diego, California and Reykjavik, Iceland (ots/PRNewswire) - - Continues Research to Validate Significance of SEQUENOM's Portfolio of Breast Cancer Genetic Discoveries SEQUENOM, Inc. (NASDAQ: SQNM) and Iceland Genomics Corporation (Iceland Genomics), a privately-held company, entered into a ...
Santa Clara, California (ots/PRNewswire) - Align Technology, Inc. (Nasdaq: ALGN), the inventor of Invisalign(R), a proprietary method of straightening teeth without wires and brackets, today filed a multi-claim lawsuit in San Francisco County Superior Court against defendants OrthoClear, Inc., OrthoClear Holdings, Inc., Muhammad Ziaullah Chishti, Bao Tran, Peter Riepenhausen, Joe Breeland, Jeff Tunnell, Christopher Kawaja, and Charles Wen. Among other things, the lawsuit ...
Carlsbad, California (ots/PRNewswire) - - Medex Commits More Than US$1.4 Million in Medical Product Contributions Medex, a global manufacturer and marketer of medical devices, announced today that it has authorized medical product donations of more than US$1.4 million to assist with relief efforts throughout tsunami-affected countries and other regions requiring assistance. Working through AmeriCares, ...
Basel, Switzerland (ots/PRNewswire) - - Study adds to the body of evidence showing the benefits of Avastin with different colorectal cancer treatment regimens A new study, presented for the first time today, shows Avastin(R) (bevacizumab, rhuMAb-VEGF) significantly increases survival in patients with ...
Basel, Switzerland (ots/PRNewswire) - - New data shows significant improvement in overall survival when Tarceva is added to chemotherapy New data, presented for the first time today, have shown that adding Tarceva (erlotinib) to chemotherapy improves survival in patients with locally advanced or metastatic pancreatic cancer(1). This is the second cancer type ...
St. Gallen, Switzerland (ots/PRNewswire) - In postmenopausal women with early breast cancer, letrozole offers better post-surgery protection against breast cancer recurrence than does tamoxifen, the current standard of care, according to data presented today at the Primary Therapy of Early Breast Cancer 9th ...